Journal Mobile Options
Table of Contents
Vol. 20, No. 5, 2005
Issue release date: September–October 2005
Fetal Diagn Ther 2005;20:442–444

Infiltrative Breast Cancer during Pregnancy and Conservative Surgery

Annane K. · Bellocq J.-P. · Brettes J.-P. · Mathelin C.
aService de Gynécologie-Obstétrique, Hôpitaux Universitaires de Strasbourg et bService d’Anatomie Pathologique, Hôpital de Hautepierre, Strasbourg, France

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Mastectomy is considered as the standard therapy for gestational breast cancer. Since radiation therapy is harmful for the fetus, conservative surgery is rarely used during pregnancy. Among 16 patients with gestational breast cancer, 10 and 6 were treated with conservative surgery and mastectomy, respectively. No local recurrences occurred with a median follow-up time of 87 months. Among the 10 patients treated with conservative surgery, 3 chose therapeutic abortion and 7 opted to continue their pregnancy. Concerning these 7 fetuses, there were no congenital anomalies, nor growth restriction. All children were normal physically and neurologically. We concluded that conservative breast surgery may be an alternative to mastectomy in the treatment of gestational breast cancer and is safe for the fetus.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. National Cancer Institute: Breast cancer in pregnancy. at:
  2. Nettleton J, Long J, Kuban D, Wu R, Shaefffer J, El-Mahdi A: Breast cancer during pregnancy: Quantifying the risk of treatment delay. Obstet Gynecol 1996;87:414–418.
  3. Keleher AJ, Theriault RL, Gwyn KM, Hunt KK, Stelling CB, Singletary SE, et al: Multidisciplinary management of breast cancer concurrent with pregnancy. J Am Coll Surg 2002;194:54–64.
  4. Kuerer HM, Gwyn K, Ames FC, Theriault RL: Conservative surgery and chemotherapy for breast carcinoma during pregnancy. Surgery 2002;131:108–110.

Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00